Understand the source comparison
Comparison of Lead Peptide Candidates for CTE Research Protocols
Before selecting a peptide for CTE research, compare the molecular targets each compound addresses, the dosing schedules validated in published TBI models, and the known limitations that affect reproducibility. | Peptide | Primary Mechanism | CTE-Relevant Targ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide for CTE research, compare the molecular targets each compound addresses, the dosing schedules validated in published TBI models, and the known limitations that affect reproducibility.
- | Peptide | Primary Mechanism | CTE-Relevant Target | Dosing Range (Preclinical) | Blood-Brain Barrier Penetration | Storage Requirement | Professional Assessment ||—|—|—|—|—|—|| Cerebrolysin | Neurotrophic factor mixture (BDNF-like, NGF-like activity) | Reduces phosphorylated tau via GSK-3β inhibition; prevents neuronal apoptosis | 2.5–5 mL/kg IV in rodents (human equivalent ≈0.4–0.8 mL/kg) | High. Low molecular weight peptides cross via receptor-mediated transcytosis | Refrigerate at 2–8°C; photosensitive. Store in amber vials | Best evidence for tau reduction in repetitive TBI models; expensive and requires IV administration || Dihexa | HGF receptor agonist; potentiates c-Met signaling | Restores synaptic density and dendritic spine formation in injured cortex | 4 mg/kg SC daily for 14 days (rodent model) | Excellent. Lipophilic structure allows passive diffusion | Store lyophilized powder at −20°C; reconstituted solution stable 28 days at 4°C | Strongest synaptogenesis data but les